当前位置：
X-MOL 学术
›
J. Contemp. Brachyther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study
Journal of Contemporary Brachytherapy ( IF 1.1 ) Pub Date : 2021-02-17 , DOI: 10.5114/jcb.2021.103580 Evelyn Martínez 1, 2 , Olatz Garin 3, 4, 5 , Yolanda Pardo 3, 4, 6 , Pablo Fernández 7 , Benjamin Guix 8 , Cristina Gutiérrez 1 , Ana Boladeras 1 , Ferran Ferrer 1 , Tania Hernández 1, 2 , Adriana Ayala 7 , Mikel Egiguren 7 , Gema Fernández 9 , Víctor Muñoz 10 , Víctor Macías 11 , Joan Pera 1 , Àngels Pont 3, 4 , Montserrat Ferrer 3, 4, 6 , Ferran Guedea 1 , ,
Journal of Contemporary Brachytherapy ( IF 1.1 ) Pub Date : 2021-02-17 , DOI: 10.5114/jcb.2021.103580 Evelyn Martínez 1, 2 , Olatz Garin 3, 4, 5 , Yolanda Pardo 3, 4, 6 , Pablo Fernández 7 , Benjamin Guix 8 , Cristina Gutiérrez 1 , Ana Boladeras 1 , Ferran Ferrer 1 , Tania Hernández 1, 2 , Adriana Ayala 7 , Mikel Egiguren 7 , Gema Fernández 9 , Víctor Muñoz 10 , Víctor Macías 11 , Joan Pera 1 , Àngels Pont 3, 4 , Montserrat Ferrer 3, 4, 6 , Ferran Guedea 1 , ,
Affiliation
Introduction
Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa.
Material and methods
Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires.
Results
A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0.028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups.
Conclusions
After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.
中文翻译：
单独采用外照射治疗与采用高剂量率近距离放射治疗的外照射治疗相比，高危局限性前列腺癌患者的五年生活质量：一项前瞻性多中心研究
引言
近距离放射疗法（BT）和外部束放射疗法（EBRT）是治疗高危前列腺癌（PCa）的有效方法。然而，这些治疗对健康相关生活质量（HRQL）的影响尚不清楚。在这项研究中，我们比较了单独的EBRT与EBRT加上高剂量率（HDR）-BT加强疗法对高危PCa患者对HRQL的影响。
材料和方法
2004年至2006年，对仅接受EBRT或EBRT + HDR-BT治疗的高危PCa患者进行了前瞻性，多中心研究。在基线（治疗前）和5年随访中定期评估HRQL，使用SF-36（v.2），EPIC和FACT-G和FACT-P问卷。
结果
该研究共纳入129名患者，其中41例接受了单独的EBRT，88例接受了EBRT + HDR-BT。所有患者均接受激素疗法。基线临床特征相似，但EBRT组的合并症平均数略高。在随访期间，唯一的组间差异是仅EBRT组的EPIC激素域恶化更大（p = 0.028）。在5年的随访中，SF-36，FACT-G和FACT-P调查表或EPIC尿失禁，尿激惹性阻塞性疾病以及肠和性领域的时间和治疗相互作用之间无显着差异。两组的肿瘤学结果相似。
结论
经过五年的随访，对于高风险的局部PCa患者，单独使用EBRT或与HDR-BT联合使用对HRQL的影响相似。但是，根据EPIC调查表，仅EBRT组的患者荷尔蒙区域恶化更为严重。
更新日期：2021-02-17
Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa.
Material and methods
Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires.
Results
A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0.028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups.
Conclusions
After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.
中文翻译：
单独采用外照射治疗与采用高剂量率近距离放射治疗的外照射治疗相比，高危局限性前列腺癌患者的五年生活质量：一项前瞻性多中心研究
引言
近距离放射疗法（BT）和外部束放射疗法（EBRT）是治疗高危前列腺癌（PCa）的有效方法。然而，这些治疗对健康相关生活质量（HRQL）的影响尚不清楚。在这项研究中，我们比较了单独的EBRT与EBRT加上高剂量率（HDR）-BT加强疗法对高危PCa患者对HRQL的影响。
材料和方法
2004年至2006年，对仅接受EBRT或EBRT + HDR-BT治疗的高危PCa患者进行了前瞻性，多中心研究。在基线（治疗前）和5年随访中定期评估HRQL，使用SF-36（v.2），EPIC和FACT-G和FACT-P问卷。
结果
该研究共纳入129名患者，其中41例接受了单独的EBRT，88例接受了EBRT + HDR-BT。所有患者均接受激素疗法。基线临床特征相似，但EBRT组的合并症平均数略高。在随访期间，唯一的组间差异是仅EBRT组的EPIC激素域恶化更大（p = 0.028）。在5年的随访中，SF-36，FACT-G和FACT-P调查表或EPIC尿失禁，尿激惹性阻塞性疾病以及肠和性领域的时间和治疗相互作用之间无显着差异。两组的肿瘤学结果相似。
结论
经过五年的随访，对于高风险的局部PCa患者，单独使用EBRT或与HDR-BT联合使用对HRQL的影响相似。但是，根据EPIC调查表，仅EBRT组的患者荷尔蒙区域恶化更为严重。
京公网安备 11010802027423号